BLAINJECTIONINJECTABLEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT (amivantamab-vmjw) is a bispecific antibody developed by Johnson & Johnson approved in May 2021 for multiple solid tumors including non-small cell lung cancer, colorectal cancer, breast cancer, and others. It functions as a bispecific antibody that simultaneously targets two distinct cancer pathways to enhance immune-mediated tumor destruction.
$0.001BPart D
PeakProduct is at peak lifecycle stage with limited Medicare Part D penetration, suggesting significant growth potential in commercial and institutional markets with expanding oncology team opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYBREVANT currently shows limited job linkage in available markets, with focus on commercial product direction roles at Johnson & Johnson. Growth trajectory and multiple indication expansion suggest emerging opportunities in medical affairs, market access, and oncology-specialized sales roles.
Product Director
Commercial
Worked on RYBREVANT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.